Angiogenesis News and Research

RSS

Angiogenesis is blood vessel formation. Tumor angiogenesis is the growth of new blood vessels that tumors need to grow. This is caused by the release of chemicals by the tumor.

Amgen, Takeda and Millennium update on phase 3 trial of Motesanib in non-small cell lung cancer

Amgen and Millennium: The Takeda Oncology Company, a subsidiary of Takeda Pharmaceutical Company Limited , today announced that enrollment in the Phase 3 MONET1 trial evaluating motesanib (AMG 706) in combination with paclitaxel and carboplatin for the first-line treatment of advanced non-small cell lung cancer (NSCLC) has been temporarily suspended following a planned safety data review of 600 patients by the study's independent Data Monitoring Committee (DMC). Motesanib is part of a broad co-development program between Amgen and Takeda.

19 Nov 2008

Cancer drug bevacizumab linked to significantly increased risk of blood clots

An analysis of randomized controlled trials indicates that use of the cancer drug bevacizumab is associated with an increased risk of venous thromboembolism (blood clots in the deep veins of the legs or in the lungs), according to an article in the November 19 issue of JAMA, the Journal of the American Medical Association.

18 Nov 2008

Blood exosomes shown to contain tumor-specific genetic information for brain cancer

Tiny vesicles called exosomes released into the bloodstream from aggressive brain tumors contain genetic signatures that may help guide future diagnosis and treatment of this deadly disease.

17 Nov 2008

Microvesicles released from glioblastoma cells carry information that may guide treatment

Microvesicles - tiny membrane-covered sacs - released from glioblastoma cells contain molecules that may provide data that can guide treatment of the deadly brain tumor.

16 Nov 2008

Chaotic vasculature hinders tumor growth

Dense networks of blood vessels thought to spur cancer's growth could actually hinder rather than promote tumor progression, according to a new study at the University of California, San Diego.

10 Nov 2008

Further evidence that angiogenesis drugs can be much more effective when combined with chemotherapy

Scientists have thought that one way to foil a tumor from generating blood vessels to feed its growth - a process called angiogenesis - was by creating drugs aimed at stopping a key vessel growth-promoting protein.

10 Nov 2008

Genentech submits application to FDA for Avastin in the most aggressive form of brain cancer

Genentech has announced that the company submitted a supplemental Biologics License Application (sBLA) to the U.S. Food and Drug Administration (FDA) for Avastin (bevacizumab) as a therapy for people with previously treated glioblastoma. If accepted by the FDA, the application would be considered for an accelerated approval that allows provisional approval of medicines for cancer or other life-threatening diseases based on preliminary evidence suggesting clinical benefit.

3 Nov 2008

Healing process found to backfire in idiopathic pulmonary fibrosis patients

A mechanism in the body which typically helps a person heal from an injury, may actually be causing patients with idiopathic pulmonary fibrosis (IPF) to get worse, researchers at the National Institute of Environmental Health Sciences (NIEHS), a part of the National Institutes of Health (NIH), and their collaborators have found.

27 Oct 2008

Targeted nanoparticles map tumor blood supply in 3-D, assess therapy

One of the defining characteristics of solid tumors is the development of a network of new blood vessels to nourish the rapidly reproducing malignant cells. Now, using a nanoparticle targeted to those new blood vessels, a joint academic-industrial research team, led by investigators from the Siteman Center of Cancer Nanotechnology Excellence, has developed a way to construct a three-dimensional (3-D) map of tumor-induced angiogenesis and monitor the effects of drug therapies on those new blood vessels.

28 Sep 2008

Benefits of combined treatments against cancer

In cancer therapy, the best results are often achieved by combining treatments such as chemotherapy, radiotherapy and surgery. This multidisciplinary approach is the focus of special symposia at the meetings of the European Society for Medical Oncology (ESMO) and the European Society for Therapeutic Radiology (ESTRO) taking place in Sweden this month.

16 Sep 2008

Investigational drug shows promise in ovarian cancer

An investigational drug that combats ovarian cancer by inhibiting the formation of new blood vessels has shown promise in a phase II trial, according to a presentation at the 33rd Congress of the European Society for Medical Oncology (ESMO) in Stockholm.

15 Sep 2008

FDA grants IND for Davanat to treat breast cancer patient

Pro-Pharmaceuticals, Inc. has announced that the U.S. Food and Drug Administration (FDA) has granted an Investigational New Drug (IND) application for use of Davanat in combination with 5-FU to treat a breast cancer patient at the Brown Cancer Center in Louisville, Kentucky. Davanat also is being administered in Phase II clinical trials for first-line treatment of colorectal and biliary cancer patients.

28 Aug 2008

Normalizing tumor vessels to improve chemotherapy drug delivery

Chemotherapy drugs often never reach the tumors they're intended to treat, and radiation therapy is not always effective, because the blood vessels feeding the tumors are abnormal-"leaky and twisty" in the words of the late Judah Folkman, MD, founder of the Vascular Biology program at Children's Hospital Boston.

25 Aug 2008

Cheap drug combo stops breast cancer in its tracks

A drug 'combo' of chemotherapy and a treatment for brittle bones has a dramatic effect on breast cancer according to researchers in the UK.

13 Aug 2008

Scientists identify microRNA that controls blood vessel development - therapeutic target for a number of diseases

Scientists from the Gladstone Institute of Cardiovascular Disease (GICD) and UCSF have identified a key regulatory factor that controls development of the human vascular system, the extensive network of arteries, veins, and capillaries that allow blood to reach all tissues and organs.

11 Aug 2008

New therapies revealed for diabetes-induced microvascular disease

New findings from Bristol scientists could lead to future treatments to prevent lower limb amputations in diabetes - which currently affect 100 people a week in the UK (source Diabetes UK). The research from the University of Bristol is published online in Circulation Research and was funded by the British Heart Foundation (BHF) and the European Vascular Genomic Network of Excellence (EVGN).

17 Jul 2008

Nanomaterials key to new strategies for blocking metastasis

A new treatment strategy using targeted nanoparticles to block metastasis with anti-cancer drugs leads to good results using significantly lower doses of toxic chemotherapy, with less collateral damage to surrounding tissue, according to a collaborative team of researchers at the Center of Nanotechnology for Treatment, Understanding, and Monitoring of Cancer at the University of California, San Diego. In designing this system, the investigators, led by David Cheresh, Ph.D., have identified what may become a generic method for using nanotechnology to target metastasis.

9 Jul 2008

EntreMed receives new patent for 2-Methoxyestradiol analogs

EntreMed, Inc. has announced the issuance of U.S. Patent No. 7,371,741 covering analogs of 2- methoxyestradiol (2ME2).

11 Jun 2008

ThromboGenics and BioInvent report positive results for anti-PlGF cancer therapeutic TB-403

ThromboGenics NV and co-development partner BioInvent International AB today reported that the results from the first Phase l study of novel anti-cancer agent TB-403 showed that it is safe and well tolerated, with pharmacokinetic properties enabling it to be developed for the treatment of cancer

3 Jun 2008

Minocycline may find new life as a stroke treatment

An old intravenous antibiotic may have new life as a stroke treatment, researchers say. Minocycline appears to reduce stroke damage in multiple ways - inhibiting white blood cells and enzymes that, at least acutely, can destroy brain tissue and blood vessels, respectively, says Dr. David Hess, chair of the Department of Neurology in the Medical College of Georgia School of Medicine.

19 May 2008